Transition zone ratio and prostate‐specific antigen density as predictors of the response of benign prostatic hypertrophy to alpha blocker and anti‐androgen therapy
Open Access
- 1 July 1997
- journal article
- clinical trial
- Published by Wiley in British Journal of Urology
- Vol. 80 (1) , 78-83
- https://doi.org/10.1046/j.1464-410x.1997.00232.x
Abstract
Objective: To determine whether transrectal ultrasonography (TRUS) can predict the clinical response of patients with benign prostatic hypertrophy (BPH) to α1‐blocker and anti‐androgen therapy.Patients and methods: From April 1994 to July 1995, 128 patients with BPH were randomized to treatment for 6 months with either tamsulosin (a long‐acting selective α1‐blocker) or allylestrenol (an anti‐androgen), with 64 patients receiving tamsulosin (0.2 mg/day) and 64 receiving allylestrenol (50 mg/day). The results of TRUS, uroflowmetry and the American Urologic Association (AUA) symptom score were compared before and after treatment. TRUS was used to calculate the transition zone (TZ) volume, transition zone ratio (TZ ratio=TZ volume/total prostate volume), total prostate volume and prostate‐specific antigen density (PSAD).Results: Both groups showed a statistically significant improvement in the AUA symptom score, quality‐of‐life (QOL) score and peak urinary flow rate (Qmax ) at 6 months (Pmax (r=−0.640, Pr=0.589, Pmax (r=0.397, Pr=−0.313, P<0.01).Conclusion: Patients with a high pretreatment PSAD responded well to anti‐androgen therapy, while those with a low PSAD responded better to α1‐blocker therapy.Keywords
This publication has 0 references indexed in Scilit: